The major mycotoxin-producing fungal genera are Aspergillus, Penicillium, Fusarium and 1 Alternaria (Moss, 1992; Sweeney and Dobson, 1998) . The growth of mycotoxigenic strains 2 of these fungi on crops, either in the field or during storage, could lead to the accumulation of 3 mycotoxins in a great variety of foods. Besides, the metabolism of ingested mycotoxins could 4 result in modified mycotoxins, as happens when aflatoxin B1 (AFB1) is converted by 5 hydroxylation to aflatoxin M1 (AFM1), mycotoxin mainly present in milk as a result of AFB1 6 metabolism in cow and other mammals (Prandini et al., 2009 ). 7 Natural occurrence of mycotoxins in food has been broadly documented. Thus, mycotoxins 8 have been widely detected in food of vegetal origin, mainly in cereals (barley, wheat, corn, 9 oat, etc.) and their by-products (Marín et Turcotte et al., 2011) . Mycotoxins also enter the human food chain via meat or 13 other animal products such as eggs, milk and cheese as a result of contaminated livestock feed 14 (Chen et al., 2012; Meyer et al., 2003) . 15 This huge variety of food matrices in which mycotoxins occur can have a very significant 16 effect on the bioavailability of mycotoxins, as complex and diverse reactions can occur 17 between mycotoxin and the food matrix, which could interfere in the way these toxins are 18 absorbed through the intestinal tract. 19 On the other hand, in the last years many structurally related compounds generated by plant 20 metabolism or by food processing have been described in mycotoxin-contaminated 21 commodities, which can co-exist together with the native toxins. These mycotoxin derivatives 22 (named conjugated or "masked" mycotoxins) may have a very different chemical behaviour, 23 thus they can easily escape routine analyses. Nevertheless, these forms could be hydrolysed to 24 their precursors in the digestive tracts of animals or could exert toxic effects comparable to 25 those imputable to free mycotoxins (De Saeger and van Egmond, 2012; Galaverna et al., 26 2009 ). This can make in some occasions very difficult to establish a clear relationship 27 between the amount of ingested toxin and the toxic effects observed, and expected, for a 28 given amount of mycotoxin. All these facts could help to explain the so-called "fumonisin 29
paradox" (i.e. the fact that apparently low contaminated commodities induce severe toxic 30 effects in animals), whereby the oral bioaccessibility of this mycotoxin could be affected by 31 different factors, one of them the uptake of fumonisin B1 (FB1) strongly conjugated to the 32 food matrix or FB1 derivatives with higher bioavailabilities (Shier, 2000) . This could also 33 happen with other mycotoxins. 34 So, knowing the amount of mycotoxin ingested may not be enough for exposure assessment. 35 Knowing the amount of toxin that becomes available for absorption through the intestinal 36 epithelium (which will be the measure of its bioaccessibility) is also required. Different 37 factors, as pH changes, enzymatic activities, etc., play an important role during the 38 gastrointestinal transit of mycotoxins and thus affect bioaccessibility. 39 To determine the bioaccessibility of mycotoxins (or in same cases, the absorption), and as a 40 first approximation to the problem, different in vitro digestion models have been used, 41 avoiding the use of more complex cell cultures or the ethically questionable use of animals in 42 in vivo experiments. 43 This review focuses on the currently available data regarding the in vitro digestion models for 44 the study of the bioaccessibility of mycotoxins, detailing the characteristics of each digestion 45 step and the importance of the physiological juices employed during digestion. The effect that 46 different factors play on the mycotoxin release from food matrix in the GI tract is also 47 considered, and existing data on bioaccessibility of the main mycotoxins are given. 48 49 2. Bioaccessibility and bioavailability 50
1
The amount of mycotoxin consumed via food does not always reflect the amount of this 2 compound that is available to exert its toxic action in a target organ of the body, as only a part 3 of the ingested compound will be bioavailable. Thus the oral bioavailability (F) of a 4 mycotoxin has been defined as the fraction of an orally ingested mycotoxin, in a certain food 5 matrix, that finally reaches the systemic circulation and is distributed throughout the entire 6 body to exert its toxic effect (Versantvoort, 2004) . This definition assumes that toxicity is 7 exerted by the parent compound and not by formed metabolites. 8 In fact, the oral bioavailability comprises three different and sequential processes (Brandon et 9 al., 2006 ): 10 a) the release of the mycotoxin from the food matrix during digestion in the GI tract. In this 11 step we are measuring the bioaccessible mycotoxin (FB). 12 b) the absorption of the bioaccessible mycotoxin through the intestinal epithelial cells of the 13 GI tract (FA), being transported to the blood (or lymph) stream. 14 c) the metabolism of the mycotoxin previous to systemic circulation (i.e., the 15 biotransformation and excretion by the intestinal epithelium or the liver), the so-called first 16 pass effect (FM). 17 So, the equation that defines the bioavailable fraction of an ingested mycotoxin, that is, the 18 fraction that reaches the systemic circulation, is defined by:
Bioaccessibility (B) has become important because it represents the amount of the mycotoxin 23 that can reach the blood after intestinal absorption. It is worth to mention that bioaccessibility 24 has been calculated only in in vitro systems. This concept is only applicable to oral exposure. 25 Other routes of exposure do not depend on the process described above. Bioaccessibility is 26
given in percentages and calculated with the following formula: 27 28 B (%) = [mycotoxinchyme] after GI digestion / [mycotoxinfood matrix] before GI digestion (2)  29  30 Physiologically speaking, bioaccessibility refers to the amount of toxin that is liberated from 31 the food matrix in the stomach and is available for absorption in the small intestine 32 (Peijnenburg and Jager, 2003; Ruby et al., 1996) . Bioaccessibility (some times called 33 digestibility) involves all the events that occur before intestinal and hepatic presystemic 34 metabolism, and that take place during the digestion of food until the macronutrients and 35 micronutrients can be assimilated into the cells of the intestinal epithelium (Fernandez-García 36 et al., 2009), and can be considered as an indicator for the maximal oral bioavailability of the 37 toxin, which can be used for realistic worst case risk assessment of the toxin in a consumer 38 product (Brandon et al., 2006 ). 39 For a mycotoxin administered in solution, as it is with drinking water, the bioaccessibility of 40 the toxin is assumed to be 100%. The toxin does not need to be mobilized from the matrix as 41 it is already in solution and, thereby, available for absorption in the intestine. After ingestion 42 of other matrices such as feed or food, the toxin may be partially or totally released from their 43 matrix during digestion in the GI tract. Only the bioaccessible fraction is available for 44 transport across the intestinal epithelium and can contribute to the internal exposure 45 (Versantvoort et al., 2004) . 46 The food matrix mainly affects the bioaccessibility, whereas absorption and metabolism 47 depend more on the toxin specific properties and on the animal physiology and, therefore, the 48 food matrix is expected to have less influence on theses processes (Brandon et al., 2006) . 49 Thus the bioaccessibility of a given mycotoxin can differ according to the considered food, as 50 has recently been demonstrated in the case of the bioaccessibilities of DON in different types 1 of Italian pasta (Raiola et al., 2012b) , of BEA in wheat crispy breads with different fiber 2 concentrations and of PAT in different apple products (Raiola et al., 3 2012a ). 4 5 3. In vitro digestion models 6 7 As described before, the bioaccessibility depends on the mycotoxin and the food matrix 8 considered. This implies that for health risk assessment of the more important mycotoxin-9 contaminated foods, it would be convenient to obtain food-specific results of oral 10 bioavailability in order to better adjust the legal limits of different food groups. food is chewed and mixed with saliva (rich in amylases) and where many polysaccharides are 26 breaking down. Then, the stomach continues smashing the food and breaking food 27 constituents mechanically and chemically with the aid of pepsine and some gastric lipases; 28 mainly protein and peptide degradation takes place, although some lipolysis also occurs 29 (Forte, 1996) . In the small intestine, where absorption of nutrients is mainly conducted, the 30 presence of lipids in the duodenum stimulates the secretion of bile salts, phosphatidylcholine, 31 and cholesterol from the gall bladder and pancreatic fluids (containing pancreatic 32 lipase/colipase, etc.) from the pancreas. Water and minerals are reabsorbed back into the 33 blood in the colon (large intestine), together with some vitamins, such as biotin and vitamin K 34 produced by bacteria (Conigrave and Young, 1996) . 35
The in vitro digestion models try to mimic this layout, especially in the first three 36 compartments of the GI tract (because mycotoxin absorption takes place mainly in the small 37 intestine 2) Digestion must be a dynamic process which helps to food disintegration and absorption. 45 Biochemical reactions, flow (hydrodynamics) and mechanical forces must be in accordance 46 with the kinetics of digestion. The rate of release (emptying) should be controlled for a 47 quick or prolonged release. 48 3) The system should allow simulating fasted or fed conditions. 49 4) The model should include anaerobic conditions and presence of typical GI microbiota. 50
5) The methodology should be easy and applicable, robust and reproducible. 1 2
Most of the designed models attempt to fulfill with the first four requirements, the latter being 3 the more difficult to achieve due to methodological complications related to the anaerobic 4 assay conditions. 5
With regard to the type of models used, most models are static GI models which simulate the 6 transit through the digestive tract by sequential (compartmentalized) exposure of the food to 7 simulated mouth, gastric and small intestinal conditions. These models are a good first 8 approximation to the problem, as they are of easy performance, and generally allow rapid 9
processing of a large number of samples, but represent in a lesser extent the GI physiological 10 reality. 11
On the other hand, dynamic GI models mimic the gradual transit of ingested compounds 12 through the simulated compartments of the GI tract, giving a more realistic simulation. The salivary α-amylase, which acts as an endoglycosidase, hydrolyzes starch and related R-46 1,4-linked polysaccharides starting the starch digestion and its transformation to 47 oligosaccharides and monosaccharides. 48 The lingual lipase is a triacylglycerol lipase that hydrolyzes dietary lipids on the carboxylic 49 ester to produce diglycerols. This hydrolysis continues in the stomach by the gastric lipase, 50 but the activity of lingual lipase has been described between pH 2 and 6.4, indicating that the 1 lingual lipase is active from the mouth to the small intestine where the activity decreases at 2 pH 6.9, while gastric lipase is still active in the intestine (Liao et al., 1984) . 3 Mucin lubricates oral surfaces, provides a protective barrier between underlying hard and soft 4 tissues and the external environment, and aid in mastication, speech and swallowing. 5
Saliva behaves as a buffer system to protect the mouth. Urea acts as a buffer present in total 6 salivary fluid; it is a product of aminoacid and protein catabolism that causes a rapid increase 7 in biofilm pH by releasing ammonia and carbon dioxide when hydrolyzed by bacterial 8 ureases. 9
In the main in vitro models, simulated saliva consists of a simplified version of this complex 10 biological fluid, containing electrolytes (KCl, KSCN, NaH2PO4, NaSO4, NaCl and NaHCO3), 11 urea and α-amylase (Gil-Izquierdo et al., 2002), whereas other models also uses uric acid and 12 mucin (Versantvoort et al., 2005) . Generally, the pH value used in this fluid is around 6.8. 13
However, salivary digestion is omitted in some in vitro models, as the TIM-1 dynamic 14 gastrointestinal model (Minekus et al., 1995) , because it is considered that it does not 15 represent great changes in matrices or components of interest. 16 17 3.1.2. Gastric juices 18 19 The gastric phase is activated when the acid secretion begins and finishes when the stomach 20 contents reach the duodenum to start the intestinal phase. Gastric juice is secreted by the 21 gastric glands of the stomach, and its production is regulated through specific neural and 22 hormonal pathways, by the eating act and by the presence of food in the stomach. In the adult 23 human, the stomach typically secretes about 2-3 liters of gastric juice per day. The three 24 major constituents of gastric juice are the mucus, the enzymes and the aqueous component, 25 the production of hydrochloric acid being a key factor as produces a significant drop in pH 26 values (Forte, 1996) . 27 Gastric mucin is a large glycoprotein which is thought to play, together with NaHCO3 28 secretion, a major role in the protection of the gastrointestinal tract from acid, proteases, 29 pathogenic microorganisms, and mechanical trauma. 30 The main enzyme in gastric juice is pepsin, although other enzymes like the gastric lipase are 31 also present. Pepsin is actually a heterogeneous group of endoproteases responsible for the 32 proteolytic activity of gastric juice (Forte, 1996 pepsin that has optimal proteolytic activity in the same pH range (i.e., pH 1-3). 38 When gastric juice is neutralized as it passes into the duodenum, pepsin is denatured and thus 39 eliminated from further digestive function. 40 The lipids are emulsified and micellizated in the stomach and the small intestine, respectively 41 (Carey et al., 1983) . The acidic pH optimum for lipolysis is from 3.5 to 6.0 and lipase activity 42 achieves a wide range of pH which allows the enzyme to act in the stomach where the 43 postprandial pH is from 4.5 to 5.5. In the small intestine the pH range is between 5.0 and 6.5 44 and lipase activity is proportional to the bile concentration after ingestion (Liao et al., 1984) . 45 In the in vitro models, gastric juice is often simulated only with a strong decrease of the pH, 46 but more complete systems include gastric juices containing pepsin (Gil-Izquierdo et al., 47 2002), and also several electrolytes (NaCl, KCl, CaCl2, NaHCO3), a lipase and bovine trypsin 48 (Versantvoort et al., 2005) . The gastric juice used in the TIM-1 dynamic gastrointestinal 49 model (Minekus et al., 1995) , one of the more complete, includes pepsin, mucin, glucose,glucuronic acid, urea, glucoseamine hydrochloride, BSA and several salts (NaCl, NaH2PO4, 1 KCl, CaCl2·2H2O, NH4Cl and HCl). 2
The pH value of the gastric juice during the in vitro GI simulation varies between models. In 3 some cases the pH is a constant value, usually low (1. Following gastric digestion, the stomach releases food into the duodenum through the pyloric 16 sphincter. Duodenum receives pancreatic enzymes from the pancreas and bile from the liver 17 and gallbladder. These fluids are important in aiding digestion and absorption. Peristalsis also 18 aids digestion and absorption by churning up food and mixing it with intestinal secretions. 19 The rest of the small intestine, located below the duodenum, consists of the jejunum and the 20 ileum. These parts of the small intestine are largely responsible for the absorption of fats and 21 other nutrients. The intestinal wall releases mucus, which lubricates the intestinal contents, 22 and water, which helps dissolve the digested fragments. Kimura et al., 1982) . This ion is usually added in simulated intestine digestion systems as 49
CaCl2, at concentrations ranging from 0.3 to 22.2 g/L (see Table 1 ).
Gastrointestinal enzymes generally have a greater resistance to irreversible denaturation, but 1 in the different parts of the intestine of healthy subjects there can be a broad pH range, which 2 can vary from pH 5.9 to pH 9 (Brownlee et al., 2010 phosphate-citrate buffer during 2 h followed by a pH decrease to 3.0 using 300 µL of ortho-47 phosphoric acid (85%), pH value that is maintained during 2 h (4 h in all, simulates gastric 48 digestion). Thereafter, the pH is increased to 6.0 by adding 600 µL NaOH (12 M) and 49 incubation for 3 h after adjusting the pH to 7.0 with 400 µL NaOh (12 M). All the incubations 1 are carried out in a water bath regulated at 37 ºC. 2
The dynamic in vitro gastrointestinal model developed at the TNO, known as TIM model has 3 been widely used in the determination of absorption of mycotoxins and other contaminants 4 (Minekus, 1998; Minekus et al, 1995 Minekus et al, , 1999 . TIM model is a multi compartmental, 5 continuous, dynamic, computer-controlled system which closely simulates the in vivo 6 conditions of the stomach and small intestine (TIM-1) and large intestine (TIM-2) of humans 7 and monogastric animals. The system simulates the peristaltic movements in the GI tract, 8 mixing and moving the contents gradually through the stomach and the intestine. This system 9 allows the simulation of the gastric empyting and intestinal transit times, and a computer-10 controlled system introduces the simulated salivary, gastric, biliary and pancreatic secretions 11 at the appropriate moment. Absorption of water and digested food compounds from the small 12 intestinal compartment is achieved by the use of hollow fiber membrane systems that are 13 hooked up at the middle and end part of the small intestine simulating the jejunum and ileum 14 (Zeijdner et al., 2004 Although simulated gastric and intestinal fluids have been used extensively in the evaluation 31 of the stability of the adsorbent-mycotoxin union (Ramos, 1996a; Scheideler, 1989) , it was 32 not until the development of the in vitro GI models described previously that effective 33 evaluation of the bioaccessibility/absorption of mycotoxins in different food matrices has 34 begun. In the next sections, available data on bioaccessibility or absorption of mycotoxins, 35 calculated using the in vitro models previously explained, will be described (Tables 2 and 3 ). 36 37 [Insert Table 2 "bioaccessibility" is applied in the field of mycotoxins, described the bioaccessibility of AFB1 4 from peanut slurries using the RIVM model for GI human tract simulation. Data obtained 5 using a low amount of AFB1 (3 ng AFB1, from 0.5 g of a peanut slurry contaminated at 6 6 µg/kg) or a higher amount (27 ng AFB1, from 4.5 g of a peanut slurry containing 6 µg/kg) 7
showed similar results of bioaccessibility, ranging between 80 and 81%, considerably higher 8 than the previous works. The bioaccessibility of AFB1 from 9 peanut slurries ranging from 0.6 9 to 14 µg/kg in the chyme (1.5 to 36 µg/kg contamination level of peanuts) was determined 10 and it was observed that a more or less constant bioaccessibility percentage of 90% at each 11 contamination level was found. The bioaccessibility rose to 104-111% when AFB1 was in a 12 food mix containing a standard meal plus the peanut slurry (1 and 3 ng AFB1 in the digestion 13 model). To test the robustness of the digestion model, some changes were applied, as the 14 decrease of the pH in the small intestinal compartment, the prolongation of the incubation 15 time in the small intestine section (4h instead 2h) bioaccessibilities of all four toxins were independent of the 3 spiking levels (2, 5 and 10 34 µg/kg for AFB1 and AFG1, and 0.6, 1.5 and 3 µg/kg for AFB2 and AFG2) and the 7 different 35 food matrices assayed. The highest AFB1 bioaccessibility value was reported in dried figs 36 (average 94.4%), whereas the lowest was detected in wheat samples (average 87.2%). Again, 37 these authors studied the effect of the addition of probiotic bacteria (from Lactobacillus and 38
Bifidobacterium genera), finding a bioaccessibility reduction that could reach in the best 39 situation a 35.6% reduction. 40 With regard to AFM1, results found in spiked and naturally contaminated UHT milk, with 41 contamination levels ranging from 0.011 to 0.939 µg/L, showed bioaccessibilities around 42 80.5-86.3% (Kabak et al., 2012a) . There were no significant differences among the spiked 43 and naturally contaminated milk samples. 44 Assuming that the bioaccessibility of AFs, including AFM1, would be around 80-90%, 45 depending on the matrices and contamination levels considered; it can be concluded that AFs 46 are almost completely released from the food matrices during digestion, implying a high 47 toxicological risk. 48 demineralised using a Chelex-100 resin, as described by Jovaní et al. (2004) . Unlike the 37 original Gil-Izquierdo method, a brief salivary digestion was added and no dialysis of the 38 pepsin digest was carried out. Commercial PAT-free apple products were contaminated with 39 50 µg PAT/L (juices) or 25 µg PAT/kg (purees) and digested. A higher bioaccessibility was 40 observed in apple juices with pulp (67.3-70.9%), followed by puree samples (55.7-58.2%). 41 Apple and pear nectar (38.9%) and clarified apple juices (25.3-28.6%) showed much lower 42 bioaccessibilities. The authors suggested that these data should be taken into account in the 43 risk assessment of this toxin, as high bioaccessibilities could be found in apple juices, 44 frequently ingested by children over 3 years. 45 Similar high PAT bioaccessibilities were found by Brandon et al. (2012) in apple products 46 using the RIVM digestion model. The bioaccessibility of PAT was assayed using two 47 different amounts of food per digestion tube (2.0 and 4.5 g, representing half a meal and a 48 normal amount of dinner). Home-made apple sauce made from apples contaminated with 49 Penicillium expansum, and spiked apple sauce and baby fruit were assayed alone or in 50 combination with other foods as yoghurt, biscuits or a standard Dutch dinner. Level of PAT 1 contamination ranged from 99.8 (spiked foods) to 110-485 µg/kg (naturally contaminated). 2 Results showed that bioaccessibility was similar for the two amounts of food and that 3 bioaccessibility values were high, ranging between 55 and 100%. 4 5 [Insert Table 3 tract determined the GI absorption of ZEA. Contaminated feed (820 µg ZEA/kg), containing 13 in its composition artificially contaminated wheat, was pumped into the GI-model. Intestinal 14 absorption of the food-released ZEA was measured analysing the dialysates at the jejunal and 15 ileal locations of the system. A 32% absorption was observed at the jejunal+ileal 16 compartment, although absorption occurred mainly in the jejunal part of the model (22%). 17 Absorption at the stomach+duodenal compartment was considerably lower (4%). Authors 18 considered that almost all the ZEA released from the food matrix during digestion was rapidly 19 absorbed, a result consistent with the in vivo data obtained by Ramos et al. (1996b) in rats that 20
showed a high rate of ZEA absorption through the intestinal lumen by a passive process. 21 These results were confirmed by Zeijdner et al. and 760 µg NIV/kg. Results showed that both toxins were simultaneously absorbed in the 39 small intestine, DON absorption being 2.4 times higher that NIV uptake. A total absorption of 40 51% was observed for DON, 44% of which takes place in the jejunum and the rest in the 41 ileum compartment. On the other hand, NIV showed a 21% absorption, 18% of which 42 corresponding to jejunum. The authors suggested that the higher absorption of DON with 43 regard to NIV (ratio 5:2) may be due to its higher hydrophobicity. 44 However, using the same in vitro model, higher values for DON absorption (68% at jejunum; 45 6% at ileum) were found later using 10-fold naturally contaminated grains (Avantaggiato et  46 al., 2007). 47 Recently, Raiola et al. (2012b) determined the bioaccessibility of DON in pasta samples using 48 the human in vitro model described by Gil-Izquierdo et al. (2002) , slightly modified. In most 49 of the samples, the in vitro model was adjusted to simulate child digestion (higher gastric pH, 50 reduced amount of pepsin, pancreatin and bile salts) and in this case the mean value for DON 1 bioaccessibility was 19.5% (ranging from 2.12% to 38.41%) for the gastric compartment and 2 9.7% for the duodenal compartment (range 1.11-17.91%). In one sample where adult 3 digestion was simulated, the bioaccessibilities found were considerably higher (32.81% 4 average; 41.49% for gastric and 24.13% for duodenal compartments). Although 5 bioaccessibilities found in the adult model were higher, authors postulate that, considering the 6 small dimension of the child intestinal tract, the released DON present in this place could 7 probably produce more damage to the intestinal enterocytes respect to that in an adult. 8
Regarding masked mycotoxins, a conjugated form of DON, the DON-3-ß-D-glucoside (DON-9 3-G) could be present in DON-contaminated plants, as glucosylation represents a major route 10 to detoxify xenobiotics for plants. In fact, it has been proven that in some cases mean DON-3-11 G contamination exceeded the DON contamination (Sasanya et al., 2008 consequently, absorption in the simulated intestinal tract is an almost complete fact and that 47 absorption of bioaccessible fumonisins would take place mainly in the upper part of the small 48 intestine. On the other hand, maximum absorption occurred in the first 2 hours of digestion. 49 These results do not agree with those from in vivo experiments, as it is known that FB1 has 50 very species-specific toxicity and a very low bioavailability when administered orally, 1 resulting from low uptake coupled with efficient biliary excretion (Shier, 2000) . Low oral FB1 2 bioavailability has been demonstrated in swine (3-6%) and laying hens 3 (0.7%) (Vudathala et al., 1994) , whereas in cows no FB1 or known metabolites were found in 4 the plasma of orally administered cows, indicating no or very limited bioavailability in 5 ruminants (Prelusky et al., 1995) . These discrepancies between the results obtained in vitro 6 and highlight the limitations of in vitro models. 7
It has been hypothesized that the totally hydrolyzed FB1 metabolite HFB1 is the real molecule 8 involved in fumonisin toxicity, is more polar than FB1 and in vivo studies demonstrated its 9
higher absorption in rats (Hopmans et al., 1997 Fusarium species are also responsible for the production of another group of bioactive 49 compounds considered as "minor" mycotoxins. This group includes enniatins (ENA, ENA1, 50 ENB and ENB1), fusaproliferin and beauvericin (Meca et al., 2010) . All of these toxins 1 belong to the group of "emerging" mycotoxins, which are neither routinely determined, nor 2 legislatively regulated; however, the evidence of their incidence is rapidly increasing. 3
Enniatins represent an emerging food safety issue because of their extensive incidence, 4 documented in recent decades, in various small grain cereals (Santini et al., 2012) . 5 Bioaccessibility of ENNs has been evaluated by the in vitro method of Gil-Izquierdo et al. 6 (2002) on spiked wheat crispy breads . Thus, breads were contaminated 7 with ENA, ENA1, ENB and ENB1 at two concentrations each (1.5 and 3.0 µmol/g) and 8
gastric and duodenal bioaccessibilities were calculated. At the gastric compartment, 9 bioaccessibility ranged between 69.0% (ENA1 at 1.5 µmol/g) and 91.0% (ENA at 3 µmol/g), 10 whereas at duodenal compartment the range was between 68.6% (ENB at 1.5 µmol/g) and 11
87.3% (ENA at 3 µmol/g). The enniatin that showed the highest bioaccessibilities was the 12 ENA, and the mean bioaccessibility considering the four compounds analyzed resulted in 13 80%. Given the fact that cereals are frequently contaminated, that it has been demonstrated 14 that ENs can exert toxic activity at low micromolar concentrations in mammalian cells (Meca 15 et al., 2011) , and that high bioaccessibilities were found these data must be taken into account 16 in future legislative actions. 17 A similar study was conducted by the same group with beauvericin The great variability of results between different mycotoxins and, for the same mycotoxin 42 among the different studied matrices, highlights the need for further studies on bioaccessibility 43 of these fungal metabolites, increasing the number and types of studied foods. The true 44 knowledge of the percentage of mycotoxin that can be absorbed in the small intestine, from 45 the initially present in food, would enable a more accurate risk assessment. 46 It is also necessary to increase the number of studies with naturally contaminated foods, as the 47 mycotoxin-matrix binding has shown to be stronger, which could affect the bioaccessibility 48 values. On the other hand, when working with spiked samples it is necessary that the 49 mycotoxin contamination level fits the natural contamination found in foods. In the same 50 sense, a special attention has to be paid to masked mycotoxins, as an overestimation of 1 bioaccessibility could occur due to an incorrect estimation of the bioaccessible toxin after the 2 digestive process, in relation to the initially known amount of toxin. 3 Determination of the internal exposure is a good approach to improve the risk assessment of a 4 mycotoxin. In vitro methods offer an appealing alternative to human and animal studies. They 5 can be rapid, simple and reasonably low in cost, can be used to perform simplified 6 experiments under uniform and well-controlled conditions, and may provide insights not 7 achievable in whole animal studies, but they are not free of some weaknesses. In one hand, in 8 many cases they do not take into account important physiological factors as the lack of 9 intestinal mucosa, enterohepatic cycling, and immune system and, in most cases they do not 10 take into account the existence of an intestinal microbiota which possesses enzymatic 11 capabilities that can decisively influence the release of the mycotoxin from the food matrix or 12 the bioconversion of these toxins in the GI tract. On the other hand, these models usually do 13 not take the large intestine into account, as absorption of toxins mainly takes place in the small 14 intestine. 15 Combined 
